A suggested modification to FIGO stage III vulvar cancer

Roman Rouzier, Mario Preti, Mario Sideri, Bernard Jean Paniel, Ronald W. Jones

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: FIGO Stage III vulvar cancer includes tumors that invade the lower urethra, vagina, or anus, and/or tumors that have metastasized to the inguino-femoral lymph nodes of one groin. We hypothesized that locally advanced stage III vulvar cancer and regional metastatic stage III vulvar cancer (lymph node involvement) have different prognoses. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) registry public use data tapes, we identified patients diagnosed with vulvar carcinoma from 1988 through 2004. Overall survival (OS) was measured as the time from diagnosis to the date of death or last follow-up. We used the Kaplan-Meier method to estimate OS and the log-rank test to assess for differences between patient groups. The staging performance was quantified with respect to discrimination. Results: The study cohort included 895 patients. The survival difference between stage III patients with locally advanced vulvar cancer and stage III patients with regional metastatic node(s) disease was highly significant (P <10- 10). The 5-year and 10-year OS of patients with locally advanced vulvar tumors without metastatic nodes were 62% and 47%, respectively. The 5-year and 10-year OS of patients with regional metastatic node(s) disease were 39% and 27%, respectively. Separating locally advanced stage III and regional metastatic stage III disease would improve discrimination (concordance index: 72% vs 69% with the actual staging system). Conclusion: Involvement of the inguinal lymph nodes in FIGO (1988) stage III patients carries a significantly worse prognosis compared with invasion of the lower urethra, vagina or anus alone. This difference in prognosis would favor restaging these two entities.

Original languageEnglish
Pages (from-to)83-86
Number of pages4
JournalGynecologic Oncology
Volume110
Issue number1
DOIs
Publication statusPublished - Jul 2008

Fingerprint

Vulvar Neoplasms
Survival
Groin
Lymph Nodes
Anal Canal
Vagina
Urethra
Neoplasms
Thigh
Registries
Epidemiology
Cohort Studies
Carcinoma

Keywords

  • Cancer
  • Locally advanced
  • Nodal metastases
  • Staging
  • Vulva

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Rouzier, R., Preti, M., Sideri, M., Paniel, B. J., & Jones, R. W. (2008). A suggested modification to FIGO stage III vulvar cancer. Gynecologic Oncology, 110(1), 83-86. https://doi.org/10.1016/j.ygyno.2008.03.001

A suggested modification to FIGO stage III vulvar cancer. / Rouzier, Roman; Preti, Mario; Sideri, Mario; Paniel, Bernard Jean; Jones, Ronald W.

In: Gynecologic Oncology, Vol. 110, No. 1, 07.2008, p. 83-86.

Research output: Contribution to journalArticle

Rouzier, R, Preti, M, Sideri, M, Paniel, BJ & Jones, RW 2008, 'A suggested modification to FIGO stage III vulvar cancer', Gynecologic Oncology, vol. 110, no. 1, pp. 83-86. https://doi.org/10.1016/j.ygyno.2008.03.001
Rouzier, Roman ; Preti, Mario ; Sideri, Mario ; Paniel, Bernard Jean ; Jones, Ronald W. / A suggested modification to FIGO stage III vulvar cancer. In: Gynecologic Oncology. 2008 ; Vol. 110, No. 1. pp. 83-86.
@article{3fec439d3b62415abc8e19d72c5e2550,
title = "A suggested modification to FIGO stage III vulvar cancer",
abstract = "Objective: FIGO Stage III vulvar cancer includes tumors that invade the lower urethra, vagina, or anus, and/or tumors that have metastasized to the inguino-femoral lymph nodes of one groin. We hypothesized that locally advanced stage III vulvar cancer and regional metastatic stage III vulvar cancer (lymph node involvement) have different prognoses. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) registry public use data tapes, we identified patients diagnosed with vulvar carcinoma from 1988 through 2004. Overall survival (OS) was measured as the time from diagnosis to the date of death or last follow-up. We used the Kaplan-Meier method to estimate OS and the log-rank test to assess for differences between patient groups. The staging performance was quantified with respect to discrimination. Results: The study cohort included 895 patients. The survival difference between stage III patients with locally advanced vulvar cancer and stage III patients with regional metastatic node(s) disease was highly significant (P <10- 10). The 5-year and 10-year OS of patients with locally advanced vulvar tumors without metastatic nodes were 62{\%} and 47{\%}, respectively. The 5-year and 10-year OS of patients with regional metastatic node(s) disease were 39{\%} and 27{\%}, respectively. Separating locally advanced stage III and regional metastatic stage III disease would improve discrimination (concordance index: 72{\%} vs 69{\%} with the actual staging system). Conclusion: Involvement of the inguinal lymph nodes in FIGO (1988) stage III patients carries a significantly worse prognosis compared with invasion of the lower urethra, vagina or anus alone. This difference in prognosis would favor restaging these two entities.",
keywords = "Cancer, Locally advanced, Nodal metastases, Staging, Vulva",
author = "Roman Rouzier and Mario Preti and Mario Sideri and Paniel, {Bernard Jean} and Jones, {Ronald W.}",
year = "2008",
month = "7",
doi = "10.1016/j.ygyno.2008.03.001",
language = "English",
volume = "110",
pages = "83--86",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A suggested modification to FIGO stage III vulvar cancer

AU - Rouzier, Roman

AU - Preti, Mario

AU - Sideri, Mario

AU - Paniel, Bernard Jean

AU - Jones, Ronald W.

PY - 2008/7

Y1 - 2008/7

N2 - Objective: FIGO Stage III vulvar cancer includes tumors that invade the lower urethra, vagina, or anus, and/or tumors that have metastasized to the inguino-femoral lymph nodes of one groin. We hypothesized that locally advanced stage III vulvar cancer and regional metastatic stage III vulvar cancer (lymph node involvement) have different prognoses. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) registry public use data tapes, we identified patients diagnosed with vulvar carcinoma from 1988 through 2004. Overall survival (OS) was measured as the time from diagnosis to the date of death or last follow-up. We used the Kaplan-Meier method to estimate OS and the log-rank test to assess for differences between patient groups. The staging performance was quantified with respect to discrimination. Results: The study cohort included 895 patients. The survival difference between stage III patients with locally advanced vulvar cancer and stage III patients with regional metastatic node(s) disease was highly significant (P <10- 10). The 5-year and 10-year OS of patients with locally advanced vulvar tumors without metastatic nodes were 62% and 47%, respectively. The 5-year and 10-year OS of patients with regional metastatic node(s) disease were 39% and 27%, respectively. Separating locally advanced stage III and regional metastatic stage III disease would improve discrimination (concordance index: 72% vs 69% with the actual staging system). Conclusion: Involvement of the inguinal lymph nodes in FIGO (1988) stage III patients carries a significantly worse prognosis compared with invasion of the lower urethra, vagina or anus alone. This difference in prognosis would favor restaging these two entities.

AB - Objective: FIGO Stage III vulvar cancer includes tumors that invade the lower urethra, vagina, or anus, and/or tumors that have metastasized to the inguino-femoral lymph nodes of one groin. We hypothesized that locally advanced stage III vulvar cancer and regional metastatic stage III vulvar cancer (lymph node involvement) have different prognoses. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) registry public use data tapes, we identified patients diagnosed with vulvar carcinoma from 1988 through 2004. Overall survival (OS) was measured as the time from diagnosis to the date of death or last follow-up. We used the Kaplan-Meier method to estimate OS and the log-rank test to assess for differences between patient groups. The staging performance was quantified with respect to discrimination. Results: The study cohort included 895 patients. The survival difference between stage III patients with locally advanced vulvar cancer and stage III patients with regional metastatic node(s) disease was highly significant (P <10- 10). The 5-year and 10-year OS of patients with locally advanced vulvar tumors without metastatic nodes were 62% and 47%, respectively. The 5-year and 10-year OS of patients with regional metastatic node(s) disease were 39% and 27%, respectively. Separating locally advanced stage III and regional metastatic stage III disease would improve discrimination (concordance index: 72% vs 69% with the actual staging system). Conclusion: Involvement of the inguinal lymph nodes in FIGO (1988) stage III patients carries a significantly worse prognosis compared with invasion of the lower urethra, vagina or anus alone. This difference in prognosis would favor restaging these two entities.

KW - Cancer

KW - Locally advanced

KW - Nodal metastases

KW - Staging

KW - Vulva

UR - http://www.scopus.com/inward/record.url?scp=45549104893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549104893&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2008.03.001

DO - 10.1016/j.ygyno.2008.03.001

M3 - Article

VL - 110

SP - 83

EP - 86

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -